Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 23, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	4,376	4,419	3,955	3,418	5,136	5,803
Market Cap Growth	11.74%	11.74%	15.72%	-33.45%	-11.50%	20.30%
Enterprise Value	5,257	5,234	4,766	4,383	5,569	6,208
Last Close Price	19.85	19.58	17.03	14.38	20.08	22.42
PE Ratio	15.44	15.41	26.52	21.91	16.52	18.38
Forward PE	11.60	10.90	10.80	9.65	14.20	18.48
PS Ratio	1.75	1.77	1.75	1.64	2.72	3.38
PB Ratio	2.36	2.38	2.28	1.92	2.82	3.69
P/TBV Ratio	4.75	4.79	4.59	4.07	4.46	6.29
P/FCF Ratio	13.73	13.87	11.48	10.51	14.11	27.13
P/OCF Ratio	9.71	9.81	8.29	7.77	10.90	17.08
PEG Ratio	1.35	1.66	1.55	2.10	1.49	2.02
EV/Sales Ratio	2.10	2.10	2.11	2.10	2.95	3.62
EV/EBITDA Ratio	8.25	8.33	7.62	7.88	10.50	12.96
EV/EBIT Ratio	10.81	10.78	9.71	10.61	13.44	15.70
EV/FCF Ratio	16.50	16.42	13.83	13.47	15.30	29.03
Debt / Equity Ratio	0.56	0.56	0.54	0.60	0.34	0.43
Debt / EBITDA Ratio	1.64	1.64	1.46	1.88	1.16	1.40
Debt / FCF Ratio	3.27	3.27	2.71	3.27	1.72	3.19
Asset Turnover	0.64	0.64	0.63	0.57	0.60	0.58
Inventory Turnover	1.82	1.82	1.76	1.70	1.73	1.70
Quick Ratio	0.60	0.60	0.82	1.05	1.31	1.05
Current Ratio	1.14	1.14	1.57	1.86	2.06	1.87
Return on Equity (ROE)	15.98%	15.98%	8.81%	8.28%	18.20%	20.11%
Return on Assets (ROA)	7.75%	7.75%	8.54%	7.04%	8.24%	8.37%
Return on Capital (ROIC)	10.81%	10.81%	11.44%	9.23%	10.97%	11.45%
Return on Capital Employed (ROCE)	19.30%	19.30%	18.70%	14.70%	16.70%	17.40%
Earnings Yield	6.55%	6.49%	3.77%	4.57%	6.05%	5.44%
FCF Yield	7.28%	7.21%	8.71%	9.52%	7.09%	3.69%
Dividend Yield	2.98%	3.26%	3.32%	3.23%	1.99%	1.63%
Payout Ratio	48.14%	48.75%	72.10%	66.49%	28.50%	25.29%
Buyback Yield / Dilution	-0.51%	-0.51%	1.13%	3.47%	2.10%	2.06%
Total Shareholder Return	2.46%	2.76%	4.45%	6.70%	4.09%	3.69%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.